July and August are very important months in hepatitis C treatment for patients. On July 18, 2017, the Food and Drug Administration (FDA) approved Gilead’s sofosbuvir/velpatasvir/voxilaprevir—brand name Vosevi–to re-treat adults with hepatitis C. In August 2017 the FDA is expected to approve AbbVie’s glecaprevir/pibrentasvir—brand name Maviret. The July and August approvals will push hepatitis C cure rates up to nearly 100%!
Gilead’s three drug combination is a pan-genotypic HCV medication co-formulated into one pill, taken once-a-day. The FDA stipulates that Vosevi is approved to treat people who have previously been treated with a DAA but who did not achieve a cure. The treatment period is 12 weeks is considered a salvage therapy—a term used for people who have failed another DAA therapy.
For the people who were treated prior with DAAs but who did not achieve a cure, 12 weeks of treatment cured up to 100% of patients.
The most common side effects were a headache, fatigue, diarrhea, and nausea.
This is very good news for the 5% to 10% of people who have failed prior DAA therapy who had few treatment options until now.
Be sure to check out our Hep C Medications Blog for more detailed information about Vosevi and the other HCV medications approved to treat hepatitis C.
Update: Since the newsletter was published Mavyret has been approved by the FDA.
AbbVie’s two drug combination is also a pan-genotypic (genotypes 1 through 6) co-formulated into one pill, once-a-day treatment for people with hepatitis C and compensated cirrhosis. The treatment period is 8 weeks and cure rates in the clinical trials were 95% to 99%.
The most common side effects were fatigue and headache.
To read the entire newsletter, click hereShare This Page